The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half

  The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their
   Ovarian Cancer Patients; However Approximately Half Encounter Access and
                            Reimbursement Hurdles

Treatment Rates with Avastin in Endometrial Cancer are Low but Most Surveyed
Oncologists Believe that Angiogenesis Inhibitors Can Play a Role in Treatment
of Endometrial Cancer, According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., Aug. 14, 2013

BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although
currently not FDA-approved for treatment of ovarian cancer, is prescribed by
approximately 70 percent of surveyed oncologists in first-line advanced
ovarian cancer. Avastin is most frequently prescribed in first-line advanced
ovarian cancer as an add-on agent to doublet platinum-based chemotherapy
followed by continued administration of Avastin as a maintenance monotherapy.
Approximately half of the surveyed oncologists who prescribe Avastin in
first-line advanced ovarian cancer indicate that they encounter reimbursement
barriers (such as prior authorization) when prescribing Avastin in this
setting.

The U.S. Physician and Payer Forum report entitled Ovarian and Endometrial
Cancer: How Will U.S. Prescriber and Payer Attitudes Toward Emerging
Antiangiogenics and Other Targeted Anticancer Agents Shape the Treatment
Landscape?  finds that current treatment of ovarian and endometrial cancers
relies heavily on generically available chemotherapies and that
carboplatin/paclitaxel is very frequently prescribed in early-stage ovarian
cancer, first-line advanced ovarian cancer and in early-stage and advanced
endometrial cancer. However, the use of Avastin for treatment of ovarian
cancer in all disease settings is common amongst surveyed oncologists and more
than 65 percent of surveyed oncologists think that treatment rates with
Avastin will increase in the next five years - primarily because they believe
Avastin will gain regulatory approval for ovarian cancer. Avastin is rarely
used by surveyed oncologists for treatment of endometrial cancer; however,
surveyed oncologists believe that angiogenesis inhibitors can play a role in
its treatment with 70 percent of surveyed oncologists responding that
targeting the vascular endothelial growth factor (VEGF) pathway will likely be
a promising treatment approach in this disease.

The report also finds that demonstrating a survival advantage over currently
available therapies is of paramount importance to most surveyed managed care
organizations' (MCOs) pharmacy directors (PDs) for formulary inclusion and
favorable tier status for ovarian cancer therapies. Surveyed MCO PDs indicate
that the cost of treatment has a smaller impact on these decisions.

"The high use of off-label Avastin in ovarian cancer means that novel
therapies for ovarian cancer, such as Amgen/Takeda Pharmaceutical's
trebananib, Merck/Endocyte's vintafolide and GlaxoSmithKline's Votrient
(pazopanib), will not only face strong competition from generically available
chemotherapies, but also from premium-priced Avastin," said Decision Resources
Senior Business Insights Analyst Karen Pomeranz, Ph.D. "Strong efficacy data
and competitive pricing of emerging therapies compared with Avastin will
encourage a high proportion of surveyed MCO PDs to offer reimbursement to
novel ovarian cancer therapies and physicians to incorporate these agents into
the treatment algorithm."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE Decision Resources

Website: http://www.decisionresources.com
 
Press spacebar to pause and continue. Press esc to stop.